Critical Shortcomings in the US' Public Health Crisis Plans
March 28th 2025Marcel Botha, CEO of 10XBeta, discusses shortcomings in the US's emergency plans for rapid innovation and manufacturing during public health crises, highlighting the need for innovation pipelines, supply chain resilience, and regulatory clarity.
Ethical Considerations for AI Use in Medication Access
March 26th 2025Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses ethical considerations surrounding AI use in medication access and how the industry can ensure that these technologies are used responsibly and equitably.
Proactively Identifying & Addressing Affordability Issues with Predictive Analytics
March 24th 2025Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses how the industry leverages data and technology to identify and address affordability issues before they become a barrier to patient access.
Practical Steps for Better Cross-Functional Collaboration
March 20th 2025Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, explores practical steps pharmaceutical executives can take to foster better collaboration within their organizations, as well as with external partners like providers and pharmacies.
The 2025 Medication Access Report: Biggest Bottlenecks for Patients
March 19th 2025Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, highlights gaps in data sharing and cross-functional collaboration as major bottlenecks that are causing delays, rework, and increased patient burden.
Understanding the Real Needs of Families: Advancing Hearing Solutions for Children and Adults
March 17th 2025Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how the focus of technology development is shifting toward ensuring safety and continuous hearing for children.
Gameto's iPSC Fertility: Overcoming Scientific Challenges
March 13th 2025Dr. Dina Radenkovic, CEO of Gameto, discusses the use of iPSCs in fertility treatments, the most significant scientific hurdles they've encountered in developing and scaling these therapies (particularly in relation to ovarian aging), and how they're addressing them.
Fast-Tracking Innovation: The Role of Regulatory Designations in DB-OTO’s Development
March 10th 2025Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how key regulatory designations, such as the FDA's Regenerative Medicine Advanced Therapy designation, facilitate accelerated development and commercialization of DB-OTO through increased collaboration with regulators.